Could the loss of revenue from the now-suspended medical device excise tax in Obamacare be offset by a new revenue stream from the industry through fiscally-motivated federal civil and criminal prosecutions launched against individual device executives for alleged “corporate wrongdoing”?
Recent guidance issued to federal law enforcement by deputy attorney general Sally Yates has, in the eyes of one medical device executive, unleashed bullying tactics among ambitious Department of Justice trial attorneys and local U.S. Attorney’s Office investigators.
